Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosalin Mishra

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Oncotarget|January 27, 2018
Genomic alterations of ERBB receptors in cancer: clinical implicationsRosalin Mishra, Ariella B Hanker, Joan T Garrett
Experimental and Therapeutic Medicine|September 21, 2012
Quercetin and sulforaphane in combination suppress the progression of melanoma through the down-regulation of matrix metalloproteinase-9Saurabh J Pradhan, Rosalin Mishra, Priyanka Sharma, et al.
Oncology Reviews|July 31, 2018
HER3 signaling and targeted therapy in cancerRosalin Mishra, Hima Patel, Samar Alanazi, et al.
Plos One|March 27, 2012
Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma modelGoutam Chakraborty, Santosh Kumar, Rosalin Mishra, et al.
Molecular Carcinogenesis|May 16, 2024
HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancerRosalin Mishra, Mary Kate Kilroy, Wasim Feroz, et al.
International Journal of Molecular Sciences|April 3, 2021
PI3K Inhibitors in Cancer: Clinical Implications and Adverse EffectsRosalin Mishra, Hima Patel, Samar Alanazi, et al.
Expert Opinion on Therapeutic Targets|December 2, 2014
The potential of class 3 semaphorins as both targets and therapeutics in cancerRosalin Mishra, Dhiraj Kumar, Deepti Tomar, et al.
Cancers|November 27, 2021
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant MelanomaHima Patel, Rosalin Mishra, Nour Yacoub, et al.
Anti-Cancer Drugs|February 27, 2023
RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cellsHima Patel, Rosalin Mishra, Adam Wier, et al.
Cancers|June 27, 2020
BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species LevelsLong Yuan, Rosalin Mishra, Hima Patel, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Oncotarget|January 27, 2018
Genomic alterations of ERBB receptors in cancer: clinical implicationsRosalin Mishra, Ariella B Hanker, Joan T Garrett
Experimental and Therapeutic Medicine|September 21, 2012
Quercetin and sulforaphane in combination suppress the progression of melanoma through the down-regulation of matrix metalloproteinase-9Saurabh J Pradhan, Rosalin Mishra, Priyanka Sharma, et al.
Oncology Reviews|July 31, 2018
HER3 signaling and targeted therapy in cancerRosalin Mishra, Hima Patel, Samar Alanazi, et al.
Plos One|March 27, 2012
Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma modelGoutam Chakraborty, Santosh Kumar, Rosalin Mishra, et al.
Molecular Carcinogenesis|May 16, 2024
HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancerRosalin Mishra, Mary Kate Kilroy, Wasim Feroz, et al.
International Journal of Molecular Sciences|April 3, 2021
PI3K Inhibitors in Cancer: Clinical Implications and Adverse EffectsRosalin Mishra, Hima Patel, Samar Alanazi, et al.
Expert Opinion on Therapeutic Targets|December 2, 2014
The potential of class 3 semaphorins as both targets and therapeutics in cancerRosalin Mishra, Dhiraj Kumar, Deepti Tomar, et al.
Cancers|November 27, 2021
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant MelanomaHima Patel, Rosalin Mishra, Nour Yacoub, et al.
Anti-Cancer Drugs|February 27, 2023
RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cellsHima Patel, Rosalin Mishra, Adam Wier, et al.
Cancers|June 27, 2020
BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species LevelsLong Yuan, Rosalin Mishra, Hima Patel, et al.
Pageof 3